{
  "meta": {
    "title": "Connective_Tissue_Disorders_Sle_Scleroderma_Sjogren_Raynaud",
    "url": "https://brainandscalpel.vercel.app/connective-tissue-disorders-sle-scleroderma-sjogren-raynaud-f6c93a9a.html",
    "scrapedAt": "2025-11-29T18:25:18.494Z"
  },
  "questions": [
    {
      "id": 19570,
      "choices": [
        {
          "id": 78241,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TLR7 </span></span></span></p>"
        },
        {
          "id": 78242,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IRF5 </span></span></span></p>"
        },
        {
          "id": 78243,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TREX1 </span></span></span></p>"
        },
        {
          "id": 78244,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TNFSF4</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old male presents with a 6-month history of photosensitivity, malar rash, and recurrent episodes of mucositis. He also reports headaches, seizures, and difficulty concentrating. Anti-nuclear antibody (ANA) testing is positive, and anti-dsDNA antibodies are present. A kidney biopsy reveals signs of lupus nephritis. A mutation analysis of which of the following genes is most likely to be informative, regarding the likely diagnosis?</span></span></p>",
      "unique_key": "Q1987168",
      "question_audio": null,
      "question_video": null,
      "map_id": 19441,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) TREX1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mutations in the TREX1 gene, which encodes a DNAse enzyme, can lead to a monogenic form of SLE with early-onset disease and severe neuropsychiatric manifestations, as seen in this case. Mutations in TLR7, IRF5, and TNFSF4 can also increase the risk of SLE, but they are not typically associated with monogenic forms of the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. TLR7:</span></strong><span style=\"font-size:12.0pt\"> Gain-of-function mutations in TLR7 are associated with SLE, but they typically lead to adult-onset disease with a milder phenotype, not the early-onset and severe neuropsychiatric manifestations seen in this patient.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. IRF5:</span></strong><span style=\"font-size:12.0pt\"> Variants in IRF5 increase susceptibility to SLE, but they are not typically associated with monogenic forms or severe neuropsychiatric presentations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. TNFSF4:</span></strong><span style=\"font-size:12.0pt\"> Mutations in TNFSF4 are linked to an increased risk of SLE, but they do not usually cause the specific combination of early-onset, neuropsychiatric symptoms, and lupus nephritis seen in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Monogenic lupus:</span></strong><span style=\"font-size:12.0pt\"> A small percentage of SLE cases are caused by single gene mutations, with TREX1 being one of the most well-characterized. Patients with monogenic lupus often present with early-onset disease and may have more severe manifestations, including neuropsychiatric involvement. Identifying a TREX1 mutation can confirm the diagnosis of monogenic lupus and has implications for prognosis and treatment.</span></span></span></p>",
      "correct_choice_id": 78243,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19571,
      "choices": [
        {
          "id": 78245,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rheumatoid arthritis </span></span></span></p>"
        },
        {
          "id": 78246,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Osteoarthritis </span></span></span></p>"
        },
        {
          "id": 78247,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Psoriatic arthritis </span></span></span></p>"
        },
        {
          "id": 78248,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SLE-associated polyarthritis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman presents with pain, swelling, and tenderness in multiple joints, particularly her wrists and knees. She reports morning stiffness lasting about 30 minutes. Physical exam reveals warmth and tenderness in the affected joints, but no obvious deformities. On further question, patient used to experience photosensitive rash usually occurring over the cheeks. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q8735304",
      "question_audio": null,
      "question_video": null,
      "map_id": 19442,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) SLE-associated polyarthritis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s history of SLE, symmetrical involvement of multiple joints, and morning stiffness suggest SLE-associated polyarthritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Rheumatoid arthritis</span></strong><span style=\"font-size:12.0pt\"> typically presents with more persistent morning stiffness and may cause joint erosions over time.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Osteoarthritis</span></strong><span style=\"font-size:12.0pt\"> primarily affects weight-bearing joints and is characterized by bony enlargement and crepitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Psoriatic arthritis</span></strong><span style=\"font-size:12.0pt\"> is often associated with skin psoriasis and typically involves the distal interphalangeal joints.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SLE-associated polyarthritis is a common manifestation of systemic lupus erythematosus (SLE), an autoimmune disease. It is important to recognize the clinical presentation of SLE-associated polyarthritis, which can include pain, swelling, and tenderness in multiple joints, along with other systemic symptoms like fatigue, fever, and rash.</span></span></span></p>",
      "correct_choice_id": 78248,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19579,
      "choices": [
        {
          "id": 78277,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tinea corporis </span></span></span></p>"
        },
        {
          "id": 78278,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Psoriasis </span></span></span></p>"
        },
        {
          "id": 78279,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discoid lupus erythematosus (DLE) </span></span></span></p>"
        },
        {
          "id": 78280,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Seborrheic dermatitis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman presents with a circular, erythematous lesion on her cheek with a raised, scaly border and a depigmented, atrophic center. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q5713491",
      "question_audio": null,
      "question_video": null,
      "map_id": 19443,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Discoid lupus erythematosus (DLE)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The classic description of a DLE lesion is a round or oval erythematous plaque with a raised, scaly border and a central area of atrophy and scarring.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tinea corporis (Ringworm):</span></strong><span style=\"font-size:12.0pt\">&nbsp;While ringworm can present as a circular lesion,&nbsp;it typically has a more active,&nbsp;inflamed border and central clearing,&nbsp;often with itching.&nbsp;The description of depigmentation and atrophy doesn&#39;t fit this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Psoriasis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Psoriasis lesions are typically well-demarcated plaques with silvery scales,&nbsp;and they don&#39;t usually present with the same degree of central atrophy as seen in DLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Seborrheic dermatitis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This condition presents as greasy,&nbsp;yellowish scales and erythema,&nbsp;usually affecting areas rich in sebaceous glands like the scalp,&nbsp;eyebrows,&nbsp;and nasolabial folds.&nbsp;The depigmentation and atrophy seen in this patient are not characteristic of seborrheic dermatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the characteristic features of DLE lesions is important for differentiating it from other skin conditions and initiating appropriate treatment.</span></span></span></p>",
      "correct_choice_id": 78279,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19581,
      "choices": [
        {
          "id": 78285,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5% </span></span></span></p>"
        },
        {
          "id": 78286,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">10% </span></span></span></p>"
        },
        {
          "id": 78287,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">20% </span></span></span></p>"
        },
        {
          "id": 78288,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50%</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the approximate percentage of patients with DPGN who either die or develop ESRD within 10 years of diagnosis?</span></span></p>",
      "unique_key": "Q8703489",
      "question_audio": null,
      "question_video": null,
      "map_id": 19444,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) 20%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Approximately 20% of individuals with DPGN experience death or ESRD within 10 years, highlighting the need for aggressive treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DPGN is a severe form of lupus nephritis with a poor prognosis. Early recognition and aggressive treatment are essential to improve outcomes.</span></span></span></p>",
      "correct_choice_id": 78287,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19583,
      "choices": [
        {
          "id": 78293,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class I </span></span></span></p>"
        },
        {
          "id": 78294,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class II </span></span></span></p>"
        },
        {
          "id": 78295,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class III </span></span></span></p>"
        },
        {
          "id": 78296,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class IV-S(A)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A renal biopsy from a patient with systemic lupus erythematosus (SLE) shows diffuse mesangial hypercellularity with mesangial immune deposits on immunofluorescence. There is no evidence of glomerular crescents or endocapillary proliferation. This finding is consistent with which class of lupus nephritis?</span></span></p>",
      "unique_key": "Q4678423",
      "question_audio": null,
      "question_video": null,
      "map_id": 19445,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Class II</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class II lupus nephritis (mesangial proliferative LN) is characterized by mesangial hypercellularity and immune deposits, without significant endocapillary or extracapillary involvement.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Class I</span></strong><span style=\"font-size:12.0pt\"> LN has normal glomeruli on light microscopy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Class III</span></strong><span style=\"font-size:12.0pt\"> LN involves focal segmental or global lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Class IV-S(A)</span></strong><span style=\"font-size:12.0pt\"> involves diffuse segmental proliferative lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Classifying lupus nephritis is crucial for determining prognosis and guiding treatment decisions.</span></span></span></p>",
      "correct_choice_id": 78294,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19585,
      "choices": [
        {
          "id": 78301,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pericardial effusion </span></span></span></p>"
        },
        {
          "id": 78302,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mitral valve regurgitation </span></span></span></p>"
        },
        {
          "id": 78303,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary hypertension </span></span></span></p>"
        },
        {
          "id": 78304,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dilated cardiomyopathy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old woman with SLE presents with fatigue, dyspnea on exertion, and orthopnea. Physical examination reveals an S3 gallop, jugular venous distension, and bilateral lower extremity edema. Which of the following is the most likely cause of her symptoms?</span></span></p>",
      "unique_key": "Q9528912",
      "question_audio": null,
      "question_video": null,
      "map_id": 19446,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Dilated cardiomyopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with heart failure, and dilated cardiomyopathy is a common cause of heart failure in SLE patients due to chronic myocarditis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pericardial effusion</span></strong><span style=\"font-size:12.0pt\"> can cause similar symptoms,&nbsp;but the S3 gallop and bilateral edema are more suggestive of left ventricular dysfunction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option B. Mitral valve</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>regurgitation&nbsp;</strong>can also cause heart failure,&nbsp;but it&#39;s less common in SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Pulmonary hypertension</span></strong><span style=\"font-size:12.0pt\"> can cause right heart failure,&nbsp;but the patient&#39;s symptoms and signs are more suggestive of left heart failure</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SLE can affect the heart in various ways, including pericarditis, myocarditis, and valvular disease. Recognizing these cardiac manifestations is essential for early intervention and preventing complications.</span></span></span></p>",
      "correct_choice_id": 78304,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19586,
      "choices": [
        {
          "id": 78305,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hydroxychloroquine </span></span></span></p>"
        },
        {
          "id": 78306,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab </span></span></span></p>"
        },
        {
          "id": 78307,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-dose glucocorticoids </span></span></span></p>"
        },
        {
          "id": 78308,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Platelet transfusion</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman with SLE presents with fatigue, pallor, and jaundice. Laboratory tests reveal anemia, elevated reticulocyte count, and a positive direct Coombs test. Which of the following is the most appropriate initial treatment?</span></span></p>",
      "unique_key": "Q4482480",
      "question_audio": null,
      "question_video": null,
      "map_id": 19447,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) High-dose glucocorticoids</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with autoimmune hemolytic anemia (AIHA), a common hematologic manifestation of SLE. High-dose glucocorticoids are the first-line treatment for AIHA in SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hydroxychloroquine</span></strong><span style=\"font-size:12.0pt\"> is used for SLE management but not as the primary treatment for AIHA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Rituximab</span></strong><span style=\"font-size:12.0pt\"> is a second-line agent for refractory AIHA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Platelet transfusion&nbsp;</span></strong><span style=\"font-size:12.0pt\">is not indicated for AIHA unless there is severe thrombocytopenia with bleeding.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">AIHA is a common hematologic manifestation of SLE and requires prompt treatment to prevent complications.</span></span></span></p>",
      "correct_choice_id": 78307,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19587,
      "choices": [
        {
          "id": 78309,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5-10% </span></span></span></p>"
        },
        {
          "id": 78310,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">25% </span></span></span></p>"
        },
        {
          "id": 78311,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">30-60% </span></span></span></p>"
        },
        {
          "id": 78312,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">80-90%</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman with systemic lupus erythematosus (SLE) presents with edema, fatigue, and foamy urine. Laboratory tests reveal proteinuria of 4.5 g/24 hours, hypoalbuminemia, and hyperlipidemia. What percentage of SLE patients with renal involvement typically develop nephrotic syndrome?</span></span></p>",
      "unique_key": "Q6516215",
      "question_audio": null,
      "question_video": null,
      "map_id": 19448,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 25%</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nephrotic syndrome is a clinical manifestation characterized by heavy proteinuria (&gt;3.5 g/24 hours),&nbsp;hypoalbuminemia,&nbsp;edema,&nbsp;and hyperlipidemia.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In SLE,&nbsp;renal involvement is common,&nbsp;with 30-60% of patients experiencing proteinuria and cellular casts.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Of those with renal involvement, approximately 25% develop nephrotic syndrome, highlighting the importance of early detection and management of lupus nephritis.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. 5-10%:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is the percentage of SLE patients who develop end-stage renal disease,&nbsp;not nephrotic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. 30-60%:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is the percentage of SLE patients who develop renal involvement (proteinuria and cellular casts),&nbsp;not specifically nephrotic syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 80-90%:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is an overestimation of the prevalence of nephrotic syndrome in SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Renal involvement is common in SLE, and a subset of these patients will develop nephrotic syndrome. Early detection and management are crucial for preventing kidney damage.</span></span></span></p>",
      "correct_choice_id": 78310,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19588,
      "choices": [
        {
          "id": 78313,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sicca syndrome </span></span></span></p>"
        },
        {
          "id": 78314,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Conjunctivitis </span></span></span></p>"
        },
        {
          "id": 78315,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Episcleritis </span></span></span></p>"
        },
        {
          "id": 78316,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinal vasculitis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old man with a history of SLE for 10 years presents to the emergency department complaining of sudden, painless vision loss in his left eye. He denies any recent trauma, eye pain, redness, or light sensitivity. On examination, his vision is 20/200 in the left eye and normal in the right eye. Funduscopic examination of the left eye reveals cotton wool spots, retinal hemorrhages, and a pale optic disc. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q4357131",
      "question_audio": null,
      "question_video": null,
      "map_id": 19450,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Retinal vasculitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinal vasculitis can lead to retinal ischemia, hemorrhage, and scarring, resulting in significant vision loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Sicca syndrome:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While common in SLE,&nbsp;it mainly causes dryness,&nbsp;irritation,&nbsp;and blurred vision,&nbsp;not sudden,&nbsp;painless vision loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Conjunctivitis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is inflammation of the conjunctiva (the membrane lining the eyelids and covering the white part of the eye).&nbsp;It usually presents with redness,&nbsp;itching,&nbsp;tearing,&nbsp;and discharge,&nbsp;not sudden vision loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Episcleritis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is inflammation of the episclera (the thin layer of tissue between the conjunctiva and the sclera,&nbsp;the white outer coating of the eye).&nbsp;It typically causes mild redness and discomfort,&nbsp;not sudden vision loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinal vasculitis is a serious complication of SLE and requires urgent evaluation and treatment to preserve vision.</span></span></span></p>",
      "correct_choice_id": 78316,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19589,
      "choices": [
        {
          "id": 78317,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary central nervous system (CNS) lymphoma </span></span></span></p>"
        },
        {
          "id": 78318,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neuropsychiatric SLE (NPSLE) </span></span></span></p>"
        },
        {
          "id": 78319,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Multiple sclerosis </span></span></span></p>"
        },
        {
          "id": 78320,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cerebral vasculitis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with a history of systemic lupus erythematosus (SLE) presents to the hospital with acute confusion, disorientation, and new-onset seizures. Brain MRI reveals multiple white matter hyperintensities. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q7990945",
      "question_audio": null,
      "question_video": null,
      "map_id": 19451,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Neuropsychiatric SLE (NPSLE)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neuropsychiatric SLE (NPSLE) is a common and potentially serious manifestation of SLE that can affect the central, peripheral, or autonomic nervous systems. The clinical presentation of NPSLE is diverse and can include cognitive dysfunction, mood disorders, psychosis, seizures, and headache. White matter hyperintensities on MRI are a characteristic finding in NPSLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Primary&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">central nervous system (</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">CNS) lymphoma:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While CNS lymphoma can occur in SLE patients,&nbsp;it is less common than NPSLE and typically presents with focal lesions rather than diffuse white matter hyperintensities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Multiple sclerosis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Multiple sclerosis can also present with white matter lesions on MRI,&nbsp;but the clinical history of SLE and other systemic symptoms makes it less likely in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cerebral vasculitis:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Cerebral vasculitis is a possible complication of SLE,&nbsp;but it usually presents with focal neurological deficits and less commonly with diffuse cognitive impairment.&nbsp;Additionally,&nbsp;MRI findings in cerebral vasculitis often show ischemic lesions rather than predominantly white matter hyperintensities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NPSLE is a common and potentially debilitating manifestation of SLE. Early recognition and treatment are essential to prevent long-term neurological damage.</span></span></span></p>",
      "correct_choice_id": 78318,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19590,
      "choices": [
        {
          "id": 78321,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Systemic Lupus Erythematosus (SLE)</span></span></span></p>"
        },
        {
          "id": 78322,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rheumatoid Arthritis (RA)</span></span></span></p>"
        },
        {
          "id": 78323,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Scleroderma</span></span></span></p>"
        },
        {
          "id": 78324,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sj&ouml;gren&#39;s Syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 37-year-old female presents with a 6-month history of joint pain, photosensitive rash, and intermittent oral ulcers. Laboratory investigations were ordered to assess for autoimmune disorders. An Antinuclear Antibody (ANA) test was performed using indirect immunofluorescence on HEp-2 cells. The result is shown in the image below. Based on the pattern observed, which of the following conditions is most likely associated with this patient&#39;s presentation?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/27/screenshot-2024-07-27-162500.png\" style=\"height:290px; width:300px\" /></span></span></p>",
      "unique_key": "Q7673218",
      "question_audio": null,
      "question_video": null,
      "map_id": 19452,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Systemic Lupus Erythematosus (SLE)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A: </span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image shows a homogenous (diffuse) nuclear staining pattern, which is commonly associated with SLE. This pattern is characterized by uniform staining of the entire nucleus, often linked to antibodies against dsDNA and histones, which are frequently seen in SLE patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Rheumatoid Arthritis (RA):</span></strong><span style=\"font-size:12.0pt\"> RA may show a positive ANA with different patterns, but the homogeneous pattern is not as strongly associated with RA as it is with SLE.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Scleroderma:</span></strong><span style=\"font-size:12.0pt\"> Scleroderma ANA patterns often include nucleolar, centromere, or speckled patterns, not typically homogenous.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sj&ouml;gren&#39;s Syndrome</span></strong><span style=\"font-size:12.0pt\">: Sj&ouml;gren&#39;s Syndrome is more commonly associated with a speckled ANA pattern and anti-SSA/Ro and anti-SSB/La antibodies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the homogeneous pattern in ANA testing is important, as it strongly suggests the possibility of SLE. However, further testing, including specific antibody tests and clinical evaluation, is necessary for a definitive diagnosis.</span></span></span></p>",
      "correct_choice_id": 78321,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19591,
      "choices": [
        {
          "id": 78325,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rheumatoid Arthritis</span></span></span></p>"
        },
        {
          "id": 78326,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Systemic Lupus Erythematosus (SLE)</span></span></span></p>"
        },
        {
          "id": 78327,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sj&ouml;gren&#39;s Syndrome</span></span></span></p>"
        },
        {
          "id": 78328,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Systemic Sclerosis (Scleroderma)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old man is evaluated for symptoms of arthritis, fatigue, and an intermittent rash. Considering his clinical presentation, an Antinuclear Antibody (ANA) test is performed, and the results show a distinct immunofluorescence pattern, shown below. Which autoimmune disease is most closely associated with this ANA pattern?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/27/screenshot-2024-07-27-162710.png\" style=\"height:197px; width:300px\" /></span></span></p>",
      "unique_key": "Q7365188",
      "question_audio": null,
      "question_video": null,
      "map_id": 19453,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Systemic Lupus Erythematosus (SLE)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong> </span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The &#39;rim&#39; or &#39;peripheral&#39; pattern in ANA immunofluorescence is characteristic of antibodies against double-stranded DNA (dsDNA) and is most closely associated with Systemic Lupus Erythematosus (SLE). This pattern shows concentrated fluorescence at the edges of the nucleus, indicative of the specific autoantibodies found in SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option A. Rheumatoid Arthritis </strong>is typically associated with rheumatoid factor and anti-CCP antibodies, not the &#39;rim&#39; ANA pattern.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sj&ouml;gren&#39;s Syndrome</span></strong><span style=\"font-size:12.0pt\"> is more commonly associated with anti-Ro/SSA and anti-La/SSB antibodies, which can produce a different ANA pattern.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Systemic Sclerosis (Scleroderma)</span></strong><span style=\"font-size:12.0pt\"> often shows ANA patterns such as the nucleolar pattern, not the &#39;rim&#39; pattern.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Identifying the rim pattern in ANA testing is a valuable clue for diagnosing SLE. It signifies the presence of specific autoantibodies targeting dsDNA, a hallmark of the disease. However, it&#39;s important to remember that not all SLE patients will exhibit this pattern, and further diagnostic workup is necessary.</span></span></span></p>",
      "correct_choice_id": 78326,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19593,
      "choices": [
        {
          "id": 78333,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">SLEDAI-2K score &le; 4 </span></span></span></p>"
        },
        {
          "id": 78334,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">No new lupus disease activity compared to the previous visit </span></span></span></p>"
        },
        {
          "id": 78335,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Physician&#39;s global assessment &le; 1 (scale 0-3) </span></span></span></p>"
        },
        {
          "id": 78336,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-double-stranded DNA antibody titer &lt; 1:80</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a criterion for defining Lupus Low Disease Activity State (LLDAS)?</span></span></p>",
      "unique_key": "Q4215154",
      "question_audio": null,
      "question_video": null,
      "map_id": 19454,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Anti-double-stranded DNA antibody titer &lt; 1:80</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While anti-dsDNA antibody titers can be helpful in monitoring SLE activity, they are not part of the formal LLDAS criteria.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><u>Explanation</u>:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The other <strong>options</strong> <strong>(A, B, and C)</strong> are all essential criteria for LLDAS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LLDAS is a state of low disease activity in SLE, defined by specific criteria including a SLEDAI-2K score &le; 4, no new disease activity compared to the previous visit, and a physician&#39;s global assessment &le; 1 (scale 0-3). Understanding these criteria is essential for monitoring disease activity and adjusting treatment plans in SLE patients.</span></span></span></p>",
      "correct_choice_id": 78336,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19595,
      "choices": [
        {
          "id": 78341,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate </span></span></span></p>"
        },
        {
          "id": 78342,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Azathioprine </span></span></span></p>"
        },
        {
          "id": 78343,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leuprolide </span></span></span></p>"
        },
        {
          "id": 78344,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Belimumab</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman with severe lupus nephritis is scheduled to begin treatment with high-dose cyclophosphamide. She is concerned about the potential side effects of this medication, particularly the risk of ovarian failure. Which of the following medications can be used to reduce this risk?</span></span></p>",
      "unique_key": "Q9007619",
      "question_audio": null,
      "question_video": null,
      "map_id": 19455,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Leuprolide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Leuprolide, a gonadotropin-releasing hormone (GnRH) agonist, can be co-administered with cyclophosphamide to protect ovarian function by suppressing ovulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>other option</strong>s do not protect against cyclophosphamide-induced ovarian failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cyclophosphamide is a potent immunosuppressive agent used in severe lupus nephritis, but it can cause premature ovarian failure. Co-administration of leuprolide can mitigate this risk and preserve fertility in young women.</span></span></span></p>",
      "correct_choice_id": 78343,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19597,
      "choices": [
        {
          "id": 78349,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">0.1-0.2 mg/kg per day </span></span></span></p>"
        },
        {
          "id": 78350,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">0.5-1 mg/kg per day </span></span></span></p>"
        },
        {
          "id": 78351,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2-3 mg/kg per day </span></span></span></p>"
        },
        {
          "id": 78352,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">5-10 mg/kg per day</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A young woman with SLE presents with new confusion, seizures, and shortness of breath. Exam shows fever, rash, and fluid overload. Labs reveal worsening kidney function and blood counts. Urine analysis suggests nephrotic range proteinuria. Biopsy confirms class IV lupus nephritis. What is the typical initial dose of glucocorticoids?</span></span></p>",
      "unique_key": "Q7544160",
      "question_audio": null,
      "question_video": null,
      "map_id": 19456,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 0.5-1 mg/kg per day</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The typical initial dose of prednisone or equivalent for severe SLE is 0.5-1 mg/kg per day. Higher doses may be used in certain situations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-dose glucocorticoids are the cornerstone of initial therapy for severe SLE manifestations due to their rapid anti-inflammatory and immunosuppressive effects. However, their use should be balanced with the risk of side effects and tapered as soon as possible.</span></span></span></p>",
      "correct_choice_id": 78350,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19599,
      "choices": [
        {
          "id": 78357,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hydroxychloroquine alone </span></span></span></p>"
        },
        {
          "id": 78358,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low-dose prednisone alone </span></span></span></p>"
        },
        {
          "id": 78359,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mycophenolate mofetil (MMF) alone </span></span></span></p>"
        },
        {
          "id": 78360,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids + cyclophosphamide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with SLE has a renal biopsy showing diffuse proliferative glomerulonephritis (DPGN) classified as ISN/RPS Class IV. Which of the following is the most appropriate induction therapy?</span></span></p>",
      "unique_key": "Q8124760",
      "question_audio": null,
      "question_video": null,
      "map_id": 19457,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Glucocorticoids + cyclophosphamide</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class IV lupus nephritis is a severe form requiring aggressive induction therapy. The combination of glucocorticoids and cyclophosphamide has been shown to be effective in reducing progression to ESRD and death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydroxychloroquine alone:</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"> </span></strong><span style=\"font-size:12.0pt\">Hydroxychloroquine is used for milder SLE manifestations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low-dose prednisone alone:&nbsp;</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low-dose prednisone is insufficient for severe nephritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mycophenolate mofetil (MMF) alone:&nbsp;</span></strong><span style=\"font-size:12.0pt\">MMF can be used but is not the standard of care for induction in Class IV LN.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Class IV lupus nephritis is the most severe form of lupus nephritis and requires aggressive induction therapy. The combination of glucocorticoids and cyclophosphamide is the standard of care for induction, followed by maintenance therapy with mycophenolate mofetil or azathioprine.</span></span></span></p>",
      "correct_choice_id": 78360,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19601,
      "choices": [
        {
          "id": 78365,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-dsDNA antibodies </span></span></span></p>"
        },
        {
          "id": 78366,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Smith antibodies </span></span></span></p>"
        },
        {
          "id": 78367,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Ro/SSA antibodies </span></span></span></p>"
        },
        {
          "id": 78368,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-histone antibodies</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old Caucasian man presents with fatigue, arthralgia, myalgia, and a low-grade fever. He has been taking hydralazine for hypertension for the past six months. Blood investigations showed Positive ANA. Given the likely diagnosis, which of the following antibodies will be present in this patient, in high titres?</span></span></p>",
      "unique_key": "Q6484012",
      "question_audio": null,
      "question_video": null,
      "map_id": 19458,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Anti-histone antibodies</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s clinical presentation, along with the positive ANA test and history of hydralazine use, strongly suggest a diagnosis of <strong>Drug-Induced Lupus Erythematosus (DILE)</strong>. Anti-histone antibodies are highly specific (nearly 100%) for DILE, although they are not always present in every case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Anti-dsDNA antibodies:</span></strong><span style=\"font-size:12.0pt\">&nbsp;These are more specific for systemic lupus erythematosus (SLE) and are less likely to be elevated in DILE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anti-Smith antibodies:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While present in SLE,&nbsp;anti-Smith antibodies are not usually elevated in DILE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Anti-Ro/SSA antibodies:</span></strong><span style=\"font-size:12.0pt\">&nbsp;These antibodies are associated with both SLE and Sj&ouml;gren&#39;s syndrome&nbsp;but are not a hallmark of DILE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the association between anti-histone antibodies and DILE is crucial for accurate diagnosis. This is especially important when a patient presents with lupus-like symptoms while taking a medication known to trigger DILE.</span></span></span></p>",
      "correct_choice_id": 78368,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19603,
      "choices": [
        {
          "id": 78373,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient has a high risk of developing systemic lupus erythematosus (SLE). </span></span></span></p>"
        },
        {
          "id": 78374,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is likely to have permanent organ damage. </span></span></span></p>"
        },
        {
          "id": 78375,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is expected to have complete resolution of symptoms upon drug withdrawal. </span></span></span></p>"
        },
        {
          "id": 78376,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient will require lifelong immunosuppressive therapy.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with DILE induced by hydralazine has been successfully treated. Which of the following statements regarding prognosis is most accurate?</span></span></p>",
      "unique_key": "Q5435110",
      "question_audio": null,
      "question_video": null,
      "map_id": 19459,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) The patient is expected to have complete resolution of symptoms upon drug withdrawal.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DILE typically resolves within weeks to months after discontinuation of the offending drug, and long-term sequelae are rare.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The risk of developing SLE is not increased after DILE. Permanent organ damage and lifelong immunosuppression are not usually necessary for DILE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The prognosis of DILE is generally good, especially with prompt recognition and discontinuation of the offending drug. Patients should be reassured that their symptoms are likely to resolve and long-term complications are rare. However, monitoring for recurrence of symptoms is important if the drug is reintroduced.</span></span></span></p>",
      "correct_choice_id": 78375,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19604,
      "choices": [
        {
          "id": 78377,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Limited cutaneous systemic sclerosis </span></span></span></p>"
        },
        {
          "id": 78378,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diffuse cutaneous systemic sclerosis </span></span></span></p>"
        },
        {
          "id": 78379,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Scleroderma sine scleroderma </span></span></span></p>"
        },
        {
          "id": 78380,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Overlap syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man with a 5-year history of Raynaud&#39;s phenomenon presents with progressive skin thickening that is limited to his fingers, hands, and face. He also reports occasional episodes of facial and hand swelling. He offers no other complaints. Physical examination reveals sclerodactyly, telangiectasias on the face, and puffy fingers. Pulmonary function tests and echocardiogram are normal. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q2663754",
      "question_audio": null,
      "question_video": null,
      "map_id": 19460,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Limited cutaneous systemic sclerosis (lcSSc)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Limited cutaneous systemic sclerosis (lcSSc)</span></strong><span style=\"font-size:12.0pt\">&nbsp;is characterized by skin thickening that is limited to the distal extremities (fingers, hands) and face. It is also associated with prominent vascular manifestations like Raynaud&#39;s phenomenon and telangiectasias. Internal organ involvement is less common and tends to occur later in the disease course compared to diffuse cutaneous SSc.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p style=\"margin-left:24px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Diffuse cutaneous systemic sclerosis (dcSSc)</span></strong><span style=\"font-size:12.0pt\">: This subtype involves skin thickening that extends proximal to the wrists and affects the trunk. Internal organ involvement is more common and occurs earlier in dcSSc compared to lcSSc.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. &nbsp;Scleroderma sine scleroderma:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This rare variant of SSc is characterized by Raynaud&#39;s phenomenon and internal organ involvement without significant skin thickening.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Overlap syndrome:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This refers to a combination of SSc with features of other connective tissue diseases like polymyositis, dermatomyositis, or systemic lupus erythematosus. There is no evidence of overlap in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the distinct clinical features of lcSSc is essential for accurate diagnosis and appropriate management.</span></span></span></p>",
      "correct_choice_id": 78377,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19606,
      "choices": [
        {
          "id": 78385,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-nuclear antibody (ANA) </span></span></span></p>"
        },
        {
          "id": 78386,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-double stranded DNA (anti-dsDNA) antibody </span></span></span></p>"
        },
        {
          "id": 78387,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-topoisomerase I (Scl-70) antibody </span></span></span></p>"
        },
        {
          "id": 78388,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-cyclic citrullinated peptide (anti-CCP) antibody</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following antibodies is considered an SSc-specific autoantibody?</span></span></span></p>",
      "unique_key": "Q9922841",
      "question_audio": null,
      "question_video": null,
      "map_id": 19461,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Anti-topoisomerase I (Scl-70) antibody</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-topoisomerase I (Scl-70) is a specific autoantibody found in patients with SSc.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Anti-nuclear antibody (</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ANA)</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">:&nbsp;</span></strong><span style=\"font-size:12.0pt\">ANA is not specific to SSc and can be found in other autoimmune diseases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anti-double stranded DNA (anti-dsDNA) antibody</span></strong><span style=\"font-size:12.0pt\">:<strong> </strong>Anti-dsDNA is specific for SLE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Anti-cyclic citrullinated peptide (anti-CCP) antibody:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Anti-CCP is specific for rheumatoid arthritis</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Identifying SSc-specific autoantibodies like anti-Scl-70 can aid in diagnosis, subtype classification, and prognostication in patients with suspected SSc.</span></span></span></p>",
      "correct_choice_id": 78387,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19610,
      "choices": [
        {
          "id": 78401,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">HLA-DRB104:01 </span></span></span></p>"
        },
        {
          "id": 78402,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">HLA-DRB107:01 </span></span></span></p>"
        },
        {
          "id": 78403,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">HLA-DRB111:04 </span></span></span></p>"
        },
        {
          "id": 78404,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">HLA-DRB115:01</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 42-year-old woman presents with Raynaud&#39;s phenomenon and progressive skin thickening of her hands. Which of the following haplotypes is most strongly associated with an increased risk of systemic sclerosis (SSc)?</span></span></p>",
      "unique_key": "Q8962300",
      "question_audio": null,
      "question_video": null,
      "map_id": 19462,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) HLA-DRB111:04 </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HLA-DRB111:04, along with DQA105:01 and DQB1*03:01, forms a haplotype that has been consistently identified as a major risk factor for SSc in various populations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. HLA-DRB104:01</span></strong><span style=\"font-size:12.0pt\"> is associated with rheumatoid arthritis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. HLA-DRB107:01&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;</span><strong><span style=\"font-size:12.0pt\">Option D. HLA-DRB115:01</span></strong><span style=\"font-size:12.0pt\"> have not been consistently linked to SSc.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understanding the genetic predisposition to SSc can help identify individuals at higher risk and potentially contribute to the development of targeted preventive strategies.</span></span></span></p>",
      "correct_choice_id": 78403,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19612,
      "choices": [
        {
          "id": 78409,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-centromere antibody (ACA) </span></span></span></p>"
        },
        {
          "id": 78410,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-topoisomerase I (Scl-70) antibody </span></span></span></p>"
        },
        {
          "id": 78411,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-RNA polymerase III antibody </span></span></span></p>"
        },
        {
          "id": 78412,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-U3-RNP (fibrillarin) antibody</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with suspected systemic sclerosis presents with a speckled pattern on antinuclear antibody (ANA) testing. Which autoantibody is most likely associated with this pattern and carries an increased risk of scleroderma renal crisis?</span></span></p>",
      "unique_key": "Q9973996",
      "question_audio": null,
      "question_video": null,
      "map_id": 19463,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Anti-RNA polymerase III antibody</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A speckled ANA pattern is commonly associated with anti-RNA polymerase III antibodies in SSc. This antibody is linked to an increased risk of developing scleroderma renal crisis, a serious complication characterized by sudden onset of malignant hypertension and acute kidney injury.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option ACA:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Centromere pattern, limited SSc, lower renal crisis risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option Scl-70:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Nucleolar/speckled nucleolar pattern, diffuse SSc, lower renal crisis risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option Anti-U3-RNP:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Nucleolar pattern, overlap syndromes, less common in SSc, lower renal crisis risk</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the association between the speckled ANA pattern, anti-RNA polymerase III antibodies, and scleroderma renal crisis is crucial for early detection and prompt intervention to prevent renal failure.</span></span></span></p>",
      "correct_choice_id": 78411,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19614,
      "choices": [
        {
          "id": 78417,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Antinuclear antibody (ANA) test </span></span></span></p>"
        },
        {
          "id": 78418,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary function tests (PFTs) </span></span></span></p>"
        },
        {
          "id": 78419,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nailfold capillaroscopy </span></span></span></p>"
        },
        {
          "id": 78420,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Echocardiogram</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman presents with a 3-year history of Raynaud&#39;s phenomenon and new onset skin tightening of the fingers. Which of the following investigations is MOST helpful in differentiating between primary Raynaud&#39;s disease and limited cutaneous systemic sclerosis (lcSSc)?</span></span></p>",
      "unique_key": "Q4583220",
      "question_audio": null,
      "question_video": null,
      "map_id": 19464,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Nailfold capillaroscopy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nailfold capillaroscopy allows direct visualization of microvascular changes in the nailfold capillaries, which are characteristic of SSc (e.g., enlarged, dilated, or absent capillaries). In primary Raynaud&#39;s disease, the nailfold capillaries are typically normal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Antinuclear antibody (ANA) test:&nbsp;</span></strong><span style=\"font-size:12.0pt\">ANA testing can be positive in both conditions but is not specific for differentiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong></span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary function tests (</span></span></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">PFTs)&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;<strong>Option D. Echocardiogram</strong> assess for internal organ involvement,&nbsp;which is more common in later stages of SSc and not helpful in early differentiation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nailfold capillaroscopy is a valuable tool in the early diagnosis of SSc, particularly in patients presenting with Raynaud&#39;s phenomenon. It can detect microvascular abnormalities before the onset of significant skin changes or internal organ involvement.</span></span></span></p>",
      "correct_choice_id": 78419,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19615,
      "choices": [
        {
          "id": 78421,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">D-penicillamine </span></span></span></p>"
        },
        {
          "id": 78422,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mycophenolate mofetil </span></span></span></p>"
        },
        {
          "id": 78423,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nintedanib </span></span></span></p>"
        },
        {
          "id": 78424,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cyclophosphamide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following medications has shown promising results in recent clinical trials for slowing the progression of SSc-associated interstitial lung disease (SSc-ILD)?</span></span></p>",
      "unique_key": "Q3620332",
      "question_audio": null,
      "question_video": null,
      "map_id": 19465,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Nintedanib</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recent clinical trials have demonstrated that nintedanib, a tyrosine kinase inhibitor, can significantly slow down the decline in lung function in patients with SSc-ILD. It can be used alone or in combination with mycophenolate mofetil.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. D-penicillamine</span></strong><span style=\"font-size:12.0pt\"> has not shown consistent benefits in recent controlled trials for SSc-ILD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Mycophenolate mofetil</span></strong><span style=\"font-size:12.0pt\"> is often used in SSc,&nbsp;but its primary role is in treating skin and other organ involvement,&nbsp;not specifically ILD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cyclophosphamide</span></strong><span style=\"font-size:12.0pt\"> is a potent immunosuppressant used for severe SSc manifestations,&nbsp;but it&#39;s not the first-line treatment for ILD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nintedanib is an emerging treatment option for SSc-ILD, offering potential hope for patients with this debilitating complication of SSc.</span></span></span></p>",
      "correct_choice_id": 78423,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19618,
      "choices": [
        {
          "id": 78433,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PAH is a rare complication of SSc. </span></span></span></p>"
        },
        {
          "id": 78434,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PAH is typically symptomatic early in its course. </span></span></span></p>"
        },
        {
          "id": 78435,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PAH accounts ~30% of deaths in SSc. </span></span></span></p>"
        },
        {
          "id": 78436,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The prognosis of PAH in SSc is generally favorable.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following statements about pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) is TRUE?</span></span></span></p>",
      "unique_key": "Q2962863",
      "question_audio": null,
      "question_video": null,
      "map_id": 19466,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) PAH accounts ~30% of deaths in SSc.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PAH is a devastating complication of SSc and is a leading cause of death in these patients, contributing to approximately 30% of mortality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong> <strong><span style=\"font-size:12.0pt\">PAH is a rare complication of SSc:&nbsp;</span></strong><span style=\"font-size:12.0pt\">PAH is not rare in SSc; it occurs in a significant minority of patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong> <strong><span style=\"font-size:12.0pt\">PAH is typically symptomatic early in its course:&nbsp;</span></strong><span style=\"font-size:12.0pt\">PAH is often asymptomatic until advanced stages,&nbsp;making early detection crucial.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. The prognosis of PAH in SSc is generally favorable:&nbsp;</span></strong><span style=\"font-size:12.0pt\">The prognosis of PAH in SSc is poor without treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PAH is a common and serious complication of SSc. Recognizing the symptoms and initiating appropriate treatment can improve outcomes and prolong survival.</span></span></span></p>",
      "correct_choice_id": 78435,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19622,
      "choices": [
        {
          "id": 78449,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mycophenolate mofetil </span></span></span></p>"
        },
        {
          "id": 78450,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eculizumab </span></span></span></p>"
        },
        {
          "id": 78451,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bosentan</span></span></span></p>"
        },
        {
          "id": 78452,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nintedanib</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with scleroderma renal crisis (SRC) is found to have activation of the complement pathway on renal biopsy. Which of the following medications might be considered as an adjunct to ACE inhibitor therapy?</span></span></p>",
      "unique_key": "Q4916295",
      "question_audio": null,
      "question_video": null,
      "map_id": 19467,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Eculizumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eculizumab, a monoclonal antibody that inhibits the complement pathway, has shown promise in some studies as an adjunct therapy for SRC, particularly in cases with evidence of complement activation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The other medications are not specifically targeted towards complement inhibition.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eculizumab is a novel therapeutic option for SRC that targets the underlying pathophysiology of the disease. Further research is needed to determine its long-term efficacy and safety in this setting.</span></span></span></p>",
      "correct_choice_id": 78450,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19623,
      "choices": [
        {
          "id": 78453,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Granulomatous inflammation</span></span></span></p>"
        },
        {
          "id": 78454,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neutrophilic infiltration of exocrine glands</span></span></span></p>"
        },
        {
          "id": 78455,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphocytic infiltration of exocrine glands</span></span></span></p>"
        },
        {
          "id": 78456,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Deposition of immune complexes in blood vessels</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old woman presents with complaints of dry mouth, dry eyes, and fatigue. On examination, you note enlarged parotid glands and dental caries. Given the likely diagnosis, which of the following is the characteristic histopathological findings?</span></span></p>",
      "unique_key": "Q1876073",
      "question_audio": null,
      "question_video": null,
      "map_id": 19468,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Lymphocytic infiltration of exocrine glands</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sj&ouml;gren&#39;s syndrome is defined by lymphocytic infiltration of the exocrine glands, particularly the salivary and lacrimal glands.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Granulomatous inflammation:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Granulomatous inflammation is seen in sarcoidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Neutrophilic infiltration of exocrine glands:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Neutrophilic infiltration is characteristic of acute infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Deposition of immune complexes in blood vessels:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Immune complex deposition is seen in vasculitis<strong>.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><span style=\"font-size:12.0pt\">: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the characteristic histopathological findings in Sj&ouml;gren&#39;s syndrome is crucial for confirming the diagnosis. A lip biopsy is commonly performed to assess the minor salivary glands for lymphocytic infiltration.</span></span></span></p>",
      "correct_choice_id": 78455,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19624,
      "choices": [
        {
          "id": 78457,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rheumatoid factor (RF)</span></span></span></p>"
        },
        {
          "id": 78458,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-nuclear antibody (ANA)</span></span></span></p>"
        },
        {
          "id": 78459,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Ro/SSA and Anti-La/SSB antibodies</span></span></span></p>"
        },
        {
          "id": 78460,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-smooth muscle antibody (ASMA)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old female is diagnosed with primary Sj&ouml;gren Syndrome after presenting with dry mouth, difficulty swallowing, and bilateral parotid gland enlargement. Which of the following tests is most specific for diagnosing primary Sj&ouml;gren Syndrome?</span></span></p>",
      "unique_key": "Q2960841",
      "question_audio": null,
      "question_video": null,
      "map_id": 19469,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Anti-Ro/SSA and Anti-La/SSB antibodies</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Ro/SSA and Anti-La/SSB antibodies are highly specific for Sj&ouml;gren Syndrome and are key serological markers in its diagnosis. Their presence, particularly in patients with typical clinical features of the syndrome, such as dry mouth (xerostomia), dry eyes (keratoconjunctivitis sicca), and glandular enlargement, strongly supports the diagnosis of primary Sj&ouml;gren Syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Rheumatoid factor (RF)</span></strong><span style=\"font-size:12.0pt\"> can be positive in Sj&ouml;gren Syndrome but is not specific as it can be positive in other autoimmune diseases, including rheumatoid arthritis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anti-nuclear antibody (ANA)</span></strong><span style=\"font-size:12.0pt\"> can be positive in a wide range of autoimmune diseases and is not specific to Sj&ouml;gren Syndrome.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Anti-smooth muscle antibody (ASMA)</span></strong><span style=\"font-size:12.0pt\"> is associated with autoimmune hepatitis and not specific for Sj&ouml;gren Syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While other tests like RF and ANA can be positive in Sj&ouml;gren&#39;s syndrome, they are not as specific as anti-Ro/SSA and anti-La/SSB antibodies. These antibodies, in combination with clinical features, are crucial for establishing the diagnosis of primary Sj&ouml;gren&#39;s syndrome.</span></span></span></p>",
      "correct_choice_id": 78459,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19626,
      "choices": [
        {
          "id": 78465,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fatigue </span></span></span></p>"
        },
        {
          "id": 78466,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Arthralgias/Arthritis </span></span></span></p>"
        },
        {
          "id": 78467,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Raynaud&#39;s phenomenon </span></span></span></p>"
        },
        {
          "id": 78468,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lung involvement</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the MOST common extraglandular manifestation in primary Sj&ouml;gren&#39;s syndrome?</span></span></p>",
      "unique_key": "Q6956727",
      "question_audio": null,
      "question_video": null,
      "map_id": 19470,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Arthralgias/Arthritis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The table shows that arthralgias/arthritis occur in 60% of primary Sj&ouml;gren&#39;s syndrome patients, making it the most common extraglandular manifestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Fatigue&nbsp;</strong>(25%), </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Raynaud&#39;s phenomenon&nbsp;</strong>(37%), </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>lung involvemen</strong>t (14%) are less common.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognizing the wide range of extraglandular manifestations in Sj&ouml;gren&#39;s syndrome is important for comprehensive patient care. While the primary symptoms involve dryness of the eyes and mouth, other organs can be affected, with arthralgias/arthritis being the most prevalent.</span></span></span></p>",
      "correct_choice_id": 78466,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19628,
      "choices": [
        {
          "id": 78473,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cryoglobulinemia-associated vasculitis </span></span></span></p>"
        },
        {
          "id": 78474,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">T-cell mediated cytotoxicity </span></span></span></p>"
        },
        {
          "id": 78475,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Ro/SSA antibody-mediated damage </span></span></span></p>"
        },
        {
          "id": 78476,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Granulomatous inflammation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with Sj&ouml;gren&#39;s syndrome presents with palpable purpura on the lower extremities, arthralgia, and peripheral neuropathy. Which of the following is the most likely underlying pathophysiology?</span></span></p>",
      "unique_key": "Q6541312",
      "question_audio": null,
      "question_video": null,
      "map_id": 19471,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Cryoglobulinemia-associated vasculitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The combination of purpura, arthralgia, and neuropathy in a Sj&ouml;gren&#39;s patient strongly suggests cryoglobulinemia-associated vasculitis, a type III hypersensitivity reaction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;T-cell mediated cytotoxicity:&nbsp;</span></strong><span style=\"font-size:12.0pt\">T-cell mediated cytotoxicity is involved in other autoimmune diseases but not the primary mechanism in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Anti-Ro/SSA antibody-mediated damage</span></strong><span style=\"font-size:12.0pt\">:<strong> </strong>Anti-Ro/SSA antibodies are associated with Sj&ouml;gren&#39;s but don&#39;t directly cause vasculitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Granulomatous inflammation:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Granulomatous inflammation is more characteristic of conditions like sarcoidosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cryoglobulinemia-associated vasculitis is a serious complication of Sj&ouml;gren&#39;s syndrome. Recognizing the associated symptoms and understanding the underlying pathophysiology is crucial for timely diagnosis and appropriate management.</span></span></span></p>",
      "correct_choice_id": 78473,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19629,
      "choices": [
        {
          "id": 78477,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-dsDNA antibodies</span></span></span></p>"
        },
        {
          "id": 78478,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Sm antibodies</span></span></span></p>"
        },
        {
          "id": 78479,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-centromere antibodies</span></span></span></p>"
        },
        {
          "id": 78480,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-Ro52 antibodies</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following autoantibodies is associated with an increased risk of multiple myeloma in Sj&ouml;gren&#39;s syndrome?</span></span></p>",
      "unique_key": "Q7105389",
      "question_audio": null,
      "question_video": null,
      "map_id": 19472,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Anti-Ro52 antibodies</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recent studies have shown that Sj&ouml;gren&#39;s syndrome patients with anti-Ro52, anti-Ro60, or anti-La autoantibodies have an increased risk of developing multiple myeloma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While the exact mechanism linking anti-Ro52 antibodies to multiple myeloma is not fully understood, this association highlights the importance of monitoring Sj&ouml;gren&#39;s patients with these antibodies for potential hematological malignancies.</span></span></span></p>",
      "correct_choice_id": 78480,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19630,
      "choices": [
        {
          "id": 78481,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcium channel blocker </span></span></span></p>"
        },
        {
          "id": 78482,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Angiotensin-converting enzyme (ACE) inhibitor </span></span></span></p>"
        },
        {
          "id": 78483,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Beta blocker </span></span></span></p>"
        },
        {
          "id": 78484,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Statin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man with a history of well-controlled hypertension on medication presents with worsening Raynaud&#39;s phenomenon over the past few months. He recently started taking a new medication for migraine prophylaxis. Which medication is most likely to be contributing to his worsening Raynaud&#39;s?</span></span></p>",
      "unique_key": "Q1053948",
      "question_audio": null,
      "question_video": null,
      "map_id": 19473,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Beta blocker</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Beta blockers:</span></strong><span style=\"font-size:12.0pt\">&nbsp;These medications are known to worsen Raynaud&#39;s phenomenon due to their vasoconstrictive effects.&nbsp;They reduce blood flow to the extremities,&nbsp;which can exacerbate the symptoms of Raynaud&#39;s.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Calcium channel blockers:</span></strong><span style=\"font-size:12.0pt\">&nbsp;These are often used to treat Raynaud&#39;s phenomenon because they promote vasodilation and improve blood flow to the extremities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Angiotensin-converting enzyme (ACE) inhibitors:</span></strong><span style=\"font-size:12.0pt\">&nbsp;These medications can also help improve blood flow,&nbsp;but they are not as commonly used for Raynaud&#39;s as calcium channel blockers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Statins:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Statins are used to lower cholesterol and are not known to worsen Raynaud&#39;s phenomenon.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is crucial to consider the potential impact of medications on Raynaud&#39;s phenomenon when managing patients with this condition. Beta blockers should be used with caution or avoided in individuals with Raynaud&#39;s, and alternative medications may need to be considered.</span></span></span></p>",
      "correct_choice_id": 78483,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19632,
      "choices": [
        {
          "id": 78489,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reassurance and observation </span></span></span></p>"
        },
        {
          "id": 78490,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate treatment with nifedipine </span></span></span></p>"
        },
        {
          "id": 78491,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Perform nailfold capillaroscopy </span></span></span></p>"
        },
        {
          "id": 78492,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Order an antinuclear antibody (ANA) test and rheumatoid factor</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman presents with a 2-year history of episodic color changes in her fingers when exposed to cold temperatures. The episodes start with blanching, followed by cyanosis, and then redness as her fingers rewarm. Physical examination reveals the changes shown in the picture. Which of the following is the most appropriate next step in differentiating primary from secondary raynaud&rsquo;s?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/01/screenshot-2024-08-01-170358.png\" style=\"height:173px; width:300px\" /></span></span></p>",
      "unique_key": "Q4726933",
      "question_audio": null,
      "question_video": null,
      "map_id": 19474,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Perform nailfold capillaroscopy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nailfold capillaroscopy is a non-invasive test that allows visualization of the microvasculature at the base of the fingernails. It is a valuable tool for differentiating primary Raynaud&#39;s phenomenon (vasospastic disorder) from secondary Raynaud&#39;s phenomenon associated with connective tissue diseases like scleroderma. In primary Raynaud&#39;s, the capillary pattern is usually normal, while in secondary Raynaud&#39;s, it often shows abnormalities like capillary dropout, dilation, and microhemorrhages.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Reassurance and observation:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While primary Raynaud&#39;s phenomenon is generally benign, it&#39;s crucial to rule out secondary causes, especially in patients with new-onset symptoms or those with additional features suggestive of a connective tissue disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Initiate treatment with nifedipine:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Nifedipine, a calcium channel blocker, can be helpful in managing Raynaud&#39;s phenomenon, but it&#39;s important to establish the diagnosis first.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Order an antinuclear antibody (ANA) test and rheumatoid factor:</span></strong><span style=\"font-size:12.0pt\">&nbsp;These tests can help identify underlying autoimmune diseases, but nailfold capillaroscopy is a more specific and sensitive test for differentiating primary and secondary Raynaud&#39;s phenomenon.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nailfold capillaroscopy is a valuable diagnostic tool for distinguishing primary and secondary Raynaud&#39;s phenomenon. Early differentiation is essential for identifying and managing any underlying connective tissue disease that may be causing the secondary Raynaud&#39;s.</span></span></span></p>",
      "correct_choice_id": 78491,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19633,
      "choices": [
        {
          "id": 78493,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nifedipine </span></span></span></p>"
        },
        {
          "id": 78494,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iloprost </span></span></span></p>"
        },
        {
          "id": 78495,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Losartan </span></span></span></p>"
        },
        {
          "id": 78496,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sildenafil</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with Raynaud&#39;s phenomenon presents with severe digital ischemia and necrosis of the fingertips. Which of the following medications is most likely to be considered for treatment in this scenario?</span></span></p>",
      "unique_key": "Q9870492",
      "question_audio": null,
      "question_video": null,
      "map_id": 19475,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Iloprost</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iloprost, a prostacyclin analog, is a potent vasodilator and can be used in severe cases of Raynaud&#39;s with digital ischemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nifedipine, losartan, and sildenafil are used in milder cases or as preventive measures.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recognize that severe Raynaud&#39;s phenomenon requires aggressive treatment with potent vasodilators like iloprost to prevent tissue loss and improve outcomes.</span></span></span></p>",
      "correct_choice_id": 78494,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19634,
      "choices": [
        {
          "id": 78497,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thermal biofeedback</span></span></span></p>"
        },
        {
          "id": 78498,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Endothelin receptor antagonists</span></span></span></p>"
        },
        {
          "id": 78499,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topical nitroglycerin ointment</span></span></span></p>"
        },
        {
          "id": 78500,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cyclophosphamide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old man with secondary Raynaud&#39;s phenomenon due to systemic sclerosis experiences severe episodes of digital ischemia, leading to fingertip ulcers. His condition has not improved with calcium channel blockers. Which of the following therapeutic options is most appropriate for managing his severe condition?</span></span></p>",
      "unique_key": "Q7568134",
      "question_audio": null,
      "question_video": null,
      "map_id": 19476,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Endothelin receptor antagonists</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Endothelin receptor antagonists (ERAs):</span></strong><span style=\"font-size:12.0pt\">&nbsp;These medications,&nbsp;such as bosentan and ambrisentan,&nbsp;are vasodilators specifically targeting the endothelin pathway.&nbsp;They are approved for the treatment of pulmonary arterial hypertension (PAH) and have shown efficacy in improving blood flow and reducing digital ulcers in patients with severe Raynaud&#39;s phenomenon </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Thermal biofeedback:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This non-pharmacological therapy can be helpful in mild to moderate Raynaud&#39;s,&nbsp;but it is unlikely to be sufficient for severe cases with digital ulcers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Topical nitroglycerin ointment:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This medication is primarily used to improve local blood flow and may be beneficial in milder cases of Raynaud&#39;s,&nbsp;but its efficacy in severe cases with ulcers is limited.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cyclophosphamide:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Cyclophosphamide is an immunosuppressant used for severe manifestations of systemic sclerosis,&nbsp;but it is not the first-line treatment for Raynaud&#39;s phenomenon.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Understand that ERAs are effective in treating severe Raynaud&#39;s phenomenon, especially in the context of systemic sclerosis. They target the endothelin pathway, which plays a key role in vasoconstriction and vascular remodelling.</span></span></span></p>",
      "correct_choice_id": 78498,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}